Veraxa to go public in $1.6bn SPAC deal with Voyager

Veraxa Biotech will gain access to $253m in cash from Voyager to advance its cancer drug pipeline.

Apr 24, 2025 - 06:00

Veraxa to go public in $1.6bn SPAC deal with Voyager

Veraxa Biotech will gain access to $253m in cash from Voyager to advance its cancer drug pipeline.

Read the original article

Tags:

Previous Article

Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing

Synthetic hormones and the future of contraception

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: As AI promises to revolutionize medical note-taking, concerns mount about accuracy and harm

STAT+: As AI promises to revolutionize medical note-tak...

Mar 28, 2023

Shorla acquires methotrexate solution from Therakind in the US

Shorla acquires methotrexate solution from Therakind in...

Oct 31, 2023

How cell and gene therapy are evolving

How cell and gene therapy are evolving

May 31, 2024